RANCHO CUCAMONGA, Calif.–(BUSINESS WIRE)–PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and its General Services Administration (GSA) and AbilityOne partner LightHouse for the Blind and Visually Impaired – San Francisco (LightHouse), today announced the successful completion of a Federal Aviation Administration (FAA) evaluation of PURE Bioscience’s PURE Hard Surface sanitizer and disinfectant product for use in FAA locations.
Following a vetting process which took several weeks, the FAA approved and announced that PURE Hard Surface was the only antimicrobial on the Environmental Protection Agency (EPA) List N (antimicrobials approved for use against COVID-19) authorized to be used in FAA locations such as airports, control towers, radar centers and regional control centers.
The lead scientist on the evaluation committee for the FAA stated: “The Federal Aviation Administration is one of 16 critical infrastructure sectors, meaning their assets, systems, and networks, whether physical or virtual, are considered so vital to the United States that their incapacitation or destruction would have a debilitating effect on security, national economic security, or national public health or safety. The arrival of COVID-19 presented unique challenges to keeping FAA personnel and equipment safe and functional and planes moving safely through the skies. Balancing the regulatory frameworks of the EPA, the CDC and the FDA, combined with issues of materials compatibility (e.g., does it harm screen coatings?), was a major technical effort for which PURE Hard Surface was uniquely prepared. Rigorous chemical and physical testing identified only one product out of hundreds on the EPA List N that met all the FAA criteria (no harm to people or equipment, no warning labels or personal protective equipment required, no odors, 30-second contact time for human coronavirus, product volume available on demand, rated for Emerging Viral Pathogens, secure supply chain and ease of use). PURE Hard Surface met and exceeded all required criteria.”
Following the success of a FAA pilot testing program, the FAA is requiring its janitorial service providers for FAA locations to sanitize daily using PURE Hard Surface. To date, there are 85 FAA locations, including major airports, that are sanitized with PURE Hard Surface.
PURE’s Chief Executive Officer and President Tom Y. Lee said, “We are proud that our technology met the needs and requirements for the Federal Aviation Administration’s antimicrobial use. PURE Bioscience is honored to be a part of the overall effort to maintain critical U.S. infrastructure. Our partnership with LightHouse makes PURE Hard Surface available to all federal government agencies through the GSA as an AbilityOne product supporting the National Industries for the Blind. The chemistry and its attributes that led to approval by the FAA committee are the same that we offer to all our customers to effectively meet their antimicrobial needs, from schools and restaurants to food processing.”
LightHouse works to advance the skills, training and opportunities for people who are blind or visually impaired. Seventy-five percent of the workforce employed to ship, bottle, and blend PURE Bioscience products are blind or visually impaired. Senior Director of Operations Brandon Cox said, “People who are blind or visually impaired are at the core of what we do. Not only are we offering secure, at-market-rate employment opportunities for this community, but we are partnering with PURE Bioscience to provide an ethical, incredibly efficient, and safe product line. And all from the Sirkin Center, our new purpose-built manufacturing plant in Alameda, right here in the Bay Area.”
About LightHouse for the Blind and Visually Impaired – San Francisco
Headquartered in San Francisco, California, LightHouse for the Blind and Visually Impaired provides education, training, advocacy, and community for blind individuals in California and around the world. Its Sirkin Center social enterprise provides essential funds to support the education, recreation, and training needs of more than 3,000 blind people every year. The Sirkin Center is the largest blind-supporting social enterprise in California and is expecting to meet increasing demand for its products for governmental, commercial, and educational customers. The organization provides training in independence, equality, and self-reliance as well as blindness skills development, access to employment, education, government, information, recreation, transportation, and the environment.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena. We provide solutions to combat the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual bacterial protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and mitigation of bacterial resistance. PURE is headquartered in Rancho Cucamonga, California (San Bernardino metropolitan area). Additional information on PURE is available at www.purebio.com
Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release concerning the Company’s expectations (including with respect to Lighthouse and FAA), plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; economic and other disruptions resulting from COVID-19; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2020, Form 10-Q for the fiscal first quarter ended October 31, 2020 and Form 10-Q for the fiscal second quarter ended January 31, 2021. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Mark Elliott, VP Finance
PURE Bioscience, Inc.
Ph: 619-596-8600 ext: 116